NPPB and hydrops fetalis: Although no trials have specifically examined the effects of combining SGLT2i with other recommended HF treatments (RAASi, ARNi, BBs, and MRAs), the recent STRONG-HF (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) study has demonstrated that a quick uptitration of guideline-directed medical therapy under strict follow-up significantly reduces the outcome of HF readmission and all-cause mortality [96].